US EPA

6183867 

Journal Article 

Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice 

Nealon, CM; Henderson-Redmond, AN; Hale, DE; Morgan, DJ 

2019 

1 

Neuropharmacology
ISSN: 0028-3908
EISSN: 1873-7064 

148 

151-159 

English 

30629988 

10.1016/j.neuropharm.2018.12.026 

WOS:000463125000015 

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060337231&doi=10.1016%2fj.neuropharm.2018.12.026&partnerID=40&md5=a4883a5408bb008273adbc329f096ecc
Exit
 

Tolerance to cannabinoid agonists can develop through desensitization of the cannabinoid receptor 1 (CB1) following prolonged administration. Desensitization results from phosphorylation of CB1 by a G protein-coupled receptor kinase (GRK), and subsequent association of the receptor with arrestin. Mice expressing a mutant form of CB1, in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Δ9-tetrahydrocannabinol (Δ9-THC). Tolerance to the antinociceptive effects of WIN55,212-2 was delayed in S426A/S430A mutants using the tail-flick and formalin tests. However, tolerance to the antinociceptive effects of once daily CP55,940 injections was not significantly delayed in S426A/S430A mutant mice using either of these tests. Interestingly, the dose response curve shifts for the hypothermic and antinociceptive effects of CP55,940 that were induced by chronic treatment with this agonist in wild-type mice were blocked in S426A/S430A mutant mice. Assessment of mechanical allodynia in mice exhibiting chronic cisplatin-evoked neuropathic pain found that tolerance to the anti-allodynic effects WIN55,212-2 but not CP55,940 was delayed in S426A/S430A mice compared to wild-type littermates. Despite these deficits in tolerance, S426A/S430A mutant mice eventually developed tolerance to both WIN55,212-2 and CP55,940 for all pain assays that were examined, suggesting that other mechanisms likely contribute to tolerance for these cannabinoid agonists. These findings suggest that GRK- and βarrestin2-mediated desensitization of CB1 may strongly contribute to the rate of tolerance to the antinociceptive effects of WIN55,212-2, and raises the possibility of agonist-specific mechanisms of cannabinoid tolerance. 

Cannabinoid; Pain; Tolerance; Antinociception; Desensitization; CB1; Mice